Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

D. Hughes; E. Faulkner; L. Annemans; L. Garrison; M. Helfand; A.P. Holtorf; J. Hornberger; D.A. Hughes; T. Li; D. Malone; K. Payne; U. Siebert; A. Towse; D. Veenstra; J. Watkins

doi:10.1016/j.jval.2012.05.006

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

D. Hughes
, E. Faulkner
, L. Annemans
, L. Garrison
, M. Helfand
, A.P. Holtorf
, J. Hornberger
, D.A. Hughes
, T. Li
, D. Malone
, K. Payne
, U. Siebert
, A. Towse
, D. Veenstra
, J. Watkins

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

Iaith wreiddiol	Saesneg
Tudalennau (o-i)	1162-1171
Cyfnodolyn	Value in Health
Cyfrol	15
Rhif cyhoeddi	8
Dynodwyr Gwrthrych Digidol (DOIs)	https://doi.org/10.1016/j.jval.2012.05.006
Statws	Cyhoeddwyd - 1 Rhag 2012

Mynediad at Ddogfen

10.1016/j.jval.2012.05.006

Dyfynnu hyn

Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D., & Watkins, J. (2012). Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health, 15(8), 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

@article{aa0dfb3e0a9f45609c4a35da46fc19d8,

title = "Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group",

author = "D. Hughes and E. Faulkner and L. Annemans and L. Garrison and M. Helfand and A.P. Holtorf and J. Hornberger and D.A. Hughes and T. Li and D. Malone and K. Payne and U. Siebert and A. Towse and D. Veenstra and J. Watkins",

year = "2012",

month = dec,

day = "1",

doi = "10.1016/j.jval.2012.05.006",

language = "English",

volume = "15",

pages = "1162--1171",

journal = "Value in Health",

issn = "1524-4733",

publisher = "Elsevier Limited",

number = "8",

}

Hughes, D, Faulkner, E, Annemans, L, Garrison, L, Helfand, M, Holtorf, AP, Hornberger, J, Hughes, DA, Li, T, Malone, D, Payne, K, Siebert, U, Towse, A, Veenstra, D & Watkins, J 2012, 'Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group', Value in Health, cyfrol. 15, rhif 8, tt. 1162-1171. https://doi.org/10.1016/j.jval.2012.05.006

Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. / Hughes, D.; Faulkner, E.; Annemans, L. et al.
Yn: Value in Health, Cyfrol 15, Rhif 8, 01.12.2012, t. 1162-1171.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

TY - JOUR

T1 - Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

AU - Hughes, D.

AU - Faulkner, E.

AU - Annemans, L.

AU - Garrison, L.

AU - Helfand, M.

AU - Holtorf, A.P.

AU - Hornberger, J.

AU - Hughes, D.A.

AU - Li, T.

AU - Malone, D.

AU - Payne, K.

AU - Siebert, U.

AU - Towse, A.

AU - Veenstra, D.

AU - Watkins, J.

PY - 2012/12/1

Y1 - 2012/12/1

U2 - 10.1016/j.jval.2012.05.006

DO - 10.1016/j.jval.2012.05.006

M3 - Article

SN - 1524-4733

VL - 15

SP - 1162

EP - 1171

JO - Value in Health

JF - Value in Health

IS - 8

ER -

Hughes D, Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP et al. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group. Value in Health. 2012 Rhag 1;15(8):1162-1171. doi: 10.1016/j.jval.2012.05.006